Fig. 2
Cost effectiveness acceptability curves. At a willingness to pay threshold of €20.000/QALY, RG-NACT is expected to be the optimal strategy with 94 and 95 % certainty under the current and full implementation scenarios respectively
Fig. 2 | BMC Cancer
